Merck consolidates global respiratory into Interpublic's Area 23

Share this article:
Merck consolidated the advertising and promotion business on its respiratory franchise to Interpublic, with Draftfcb Healthcare's Area 23 serving as lead agency. 

The assignment, which includes blockbuster brands like Singulair, Nasonex and newly-launched Dulera, spans healthcare professional and consumer advertising, medical education and managed care for asthma, allergy and COPD brands. It was previously split between several agencies: Juice handled Singulair, having relieved Draftfcb of the business back in 1998; DDB handled Nasonex; and CDM Princeton handled Dulera (Zenhale, ex-US), which launched for asthma last year and is now pursuing a COPD indication. In addition, the account includes Merck's investigational oral allergy immunotherapy tablet, now in phase 3 clinical trials, which was previously handled by LLNS. 

Draftfcb handles the advertising business on Merck's cardiovascular and metabolic franchise, including Januvia. 

“Merck has been a long-standing client of the Draftfcb Healthcare network,” said Dana Maiman, CEO of Draftfcb Healthcare. “As a matter of fact, it was our first client more than 30 years ago and we are honored to deepen our incredibly successful partnership with them.”

In fact, both Area 23 co-managing directors -- EVP Renee Mellas and creative director Tim Hawkey -- are old Draftfcb hands who came up in the business working on Merck brands like Zocor and Fosamax. The full-service spinoff shop launched in 2007.
Share this article:

Email Newsletters

More in News

Eli Lilly and BI's Jardiance hits shelves

Eli Lilly and BI's Jardiance hits shelves

The new SGLT-2 inhibitor is on shelves less than a month after FDA approval.

PhRMA Urges Court to Reject Off-Label Promotion Case

PhRMA Urges Court to Reject Off-Label Promotion Case

The Pharmaceutical Research and Manufacturers of America (PhRMA) says a California federal court should dismiss a whistleblower's False Claims Act suit against three drug companies on First Amendment grounds

Five things for Pharma Marketers to know: Tuesday, August 26

Five things for Pharma Marketers to know: Tuesday, ...

Merck and Pfizer pursue new pembrolizumab research, black box warnings are linked to fewer court visits, and the WHO says it needs $430M to fight Ebola.